Latest Breaking News On - Phase 2 regain trial crb3180015 jrcts031190103 - Page 1 : vimarsana.com

Second-line treatment with regorafenib displayed safety in patients with advanced hepatocellular carcinoma who were not eligible for treatment on the phase 3 RESORCE trial, according to data from the phase 2 REGAIN trial.

Comunidad autonoma de catalunaKeisuke korokiSchool of medicine at chiba universityDepartment of gastroenterologyInternational liver cancer association conferenceLiver cancer associationGraduate schoolChiba universityBarcelona clinic liver cancerHepatocellular carcinomaPhase 3 resorce trial nct01774344Phase 2 regain trial crb3180015 jrcts031190103